Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest cardiac arrhythmia Stories

2011-12-05 13:11:00

VANCOUVER, Dec. 5, 2011 /PRNewswire/ - Heart Force Medical Inc., a Vancouver-based company that has developed a non-invasive cardiac assessment, monitoring and screening device, is pleased to announce that Dr. Jonathan Steinberg, M.D., F.A.C.C. has agreed to join the Company's Clinical Advisory Board. Dr. Jonathan Steinberg is a cardiologist, heart rhythm specialist, and Professor of Medicine at Columbia University, College of Physicians and Surgeons of New York. He also serves as...

2011-12-05 02:00:00

LONDON, December 5, 2011 /PRNewswire/ -- - Atrial Fibrillation (AF) will affect 1 in 4 people in the UK and increases the risk of stroke by nearly 500%; the number of AF patients in the UK is expected to more than double by 2050 - AF is vastly under-treated, only 18 per cent of UK patients with AF receive treatment that adequately reduces their elevated risk of stroke - Adherence to current treatment guidelines and routine pulse checks in primary care could prevent...

2011-11-21 08:44:00

CLEVELAND, Nov. 21, 2011 /PRNewswire/ -- ChanRx is developing a superior drug for treatment of atrial fibrillation (AFIB), and has closed its Series A funding with investments from Sante Ventures and company founder, Dr. Arthur "Buzz" Brown. The company, a spin out of Cleveland-based ChanTest, will use the funding to further evaluate the safety and efficacy of its proprietary AFIB drug, vanoxerine. (Logo: http://photos.prnewswire.com/prnh/20111121/DC10359LOGO) AFIB is the most...

2011-11-16 08:46:15

(Ivanhoe Newswire) — About 7 percent of people in the U.S. who have sudden cardiac arrest outside of the hospital survive to hospital discharge, and according to this study, a wearable defibrillator can prevent sudden death in these people. Wearable cardioverter defibrillators are used by people who may be at higher risk for sudden cardiac arrest, including those with weakened heart function, awaiting cardiac transplant or with a condition that prevents or delays them from receiving...

2011-11-16 07:00:00

ATLANTA, Nov. 16, 2011 /PRNewswire/ -- CorMatrix Cardiovascular, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted the company full IDE approval for its ongoing multi-center, prospective, randomized clinical trial aiming to demonstrate the safety and efficacy of the CorMatrix ECM for Pericardial Closure to reduce the incidence of new onset postoperative atrial fibrillation following isolated primary coronary artery bypass graft (CABG) surgery. CorMatrix...

2011-11-14 11:30:30

A wearable defibrillator can prevent sudden death in people with dangerous heart arrhythmias, according to research presented at the American Heart Association's Scientific Sessions 2011. Wearable cardioverter defibrillators are used by people who may be at higher risk for sudden cardiac arrest, including those with weakened heart function, awaiting cardiac transplant or with a condition that prevents or delays them from receiving an implanted defibrillator. The device monitors heart...

2011-11-10 09:10:00

TORONTO, Nov. 10, 2011 /PRNewswire/ - Biosign Technologies Inc. (TSXV: BIO) a company focused on non-invasive monitoring of common health risks associated with blood pressure, life style and medication, is pleased to announce they have developed proprietary algorithms that can be utilized on the UFIT generated pulse waveform as a prescreening tool for arrhythmia. Biosign has published today "UFIT® Detection of Instantaneous Arrhythmic and Amplitude Anomalies" a 916...

2011-11-09 07:30:00

ANN ARBOR, Mich., Nov. 9, 2011 /PRNewswire/ -- Everist Genomics, a rapidly growing personalized medicine company developing and commercializing innovative diagnostics and prognostics, today announced plans to commercialize its CardioDefender diagnostic system. CardioDefender is the first FDA-approved and CE mark-registered smartphone ECG system to provide physicians and patients with hospital-quality heart rhythm monitoring outside of the hospital setting. The system incorporates...

2011-11-08 07:00:00

MARLBOROUGH, Mass., Nov. 8, 2011 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight(TM) Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announces that its HeartLight EAS will be discussed as a state-of-the-art technology and featured in a patient case presentation at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, November 7-11, San Francisco, CA. TCT is...

2011-11-04 12:43:00

RARITAN, N.J., Nov. 4, 2011 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved XARELTO® to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. XARELTO® is the only oral anticoagulant approved in the U.S. that offers once-daily dosing, without the need for routine blood monitoring. To view the multimedia assets associated with this release,...